Ashlee Orndorff, APRN
Nurse Practitioner · Kansas City, KSNPI 1235731332
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,127 of the $6,799 with a category attached, or 60.7%. 18 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 33.1% of the total. Reporting peaked in 2024 at $3,682 and has fallen 56.7% since, to $1,594 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 120 payments — averaging $56.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Medtronic$1K
- Cequr Corporation$989
- Dexcom, Inc.$812
- Sanofi-aventis U.S. LLC$399
- Novo Nordisk$231
- plus $808 from 12 others
What the payments were for
- Speaking & faculty fees$2634%
- Travel & lodging$2,40935%
- Food & beverage$4,12761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 18 | $2,249 |
| Medtronic | 15 | $1,311 |
| Cequr Corporation | 4 | $989 |
| Dexcom, Inc. | 33 | $812 |
| Sanofi-aventis U.S. LLC | 8 | $399 |
| Novo Nordisk | 9 | $231 |
| Lilly USA, LLC | 4 | $175 |
| Corcept Therapeutics | 7 | $130 |
| Abbott | 6 | $122 |
| Amgen | 1 | $87 |
| Insulet Corporation | 4 | $86 |
| Sequel Med Tech, LLC | 3 | $65 |
| Chiesi USA, Inc. | 2 | $38 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,937
- CeQur Simplicity$955
- MINIMED 780G$701
- TZIELD$251
- DEXCOM G6 TRANSMITTER$152
- Saxenda$120
- MOUNJARO$113
How this compares
$6,799 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 282 | $375,459 |
| MounjaroTirzepatide | 191 | $266,719 |
| JardianceEmpagliflozin | 139 | $170,690 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 89 | $88,515 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 44 | $82,514 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 47 | $78,200 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $67,852 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $57,281 |
| FarxigaDapagliflozin Propanediol | 40 | $47,328 |
| ForteoTeriparatide | 11 | $44,741 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $40,552 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $39,265 |
| TrulicityDulaglutide | 28 | $31,557 |
| RybelsusSemaglutide | 26 | $29,048 |
| Novolog FlexpenInsulin Aspart | 65 | $26,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $231 | $487,021352 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $175 | $355,666266 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $399 | $40,55222 claims |
| Cequr CorporationCequr Simplicity | $989 | $14,81023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Kansas City
- Dana MillerKansas City$13K
- Jason OralloKansas City$10K
- Paul WohletzKansas City$6K
- Emily OstranderKansas City$5K
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.